A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2015
At a glance
- Drugs PF 4856884 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 13 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2011 Planned end date changed from 1 Mar 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 12 Nov 2010 Planned end date changed from 1 Oct 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.